The principal aim of the study is to demonstrate that Rostafuroxin is able to induce a more
pronounced reduction of arterial blood pressure respect to Losartan, in hypertensive patients
carrying at least one of the pre-specified gene mutations. In previous studies has been
demonstrated that these mutations are able to induce specific alterations inducing an
increase of sodium (Na) reabsorption at renal tubular level and an increase of arterial blood
pressure. Pilot studies have demonstrated that Rostafuroxin is able to reduce the impact of
these alterations, and so directly reverse the increase in blood pressure.